Selectivity of PAR1 expression in tumor samples, its invasive potential shown in breast cancer cell lines, and the important role played by EGFR/HER2 as downstream transactivators of PAR1, indeed explains the positive correlation we found, between the expression of prognostic factors conveying poor disease outcome and poor tumour differentiation [15,16,24]. The gene discussed is F2R; the disease is neoplasm.